Literature DB >> 26563147

A pilot study to improve adherence among MS patients who discontinue treatment against medical advice.

Jared Bruce1, Amanda Bruce2,3, Sharon Lynch4, Lauren Strober5, Sean O'Bryan6, Deborah Sobotka7, Joan Thelen8, Abigail Ness8, Morgan Glusman8, Kathy Goggin9,10, Andrea Bradley-Ewing9, Delwyn Catley8.   

Abstract

Between 30 and 50% of MS patients may prematurely discontinue disease modifying therapies. Little research has examined how to best talk with patients who have discontinued treatment against medical advice. The aim of this pilot study was to determine whether telephone counseling increases disease modifying therapy (DMT) re-initiation among nonadherent patients with multiple sclerosis (MS). Participants were eligible if they had relapsing-remitting disease, had stopped taking a DMT, and had no plan to re-initiate treatment despite a provider recommendation. Following a baseline assessment, 81 patients were randomly assigned to either five 20 min, weekly sessions of Motivational Interviewing/Cognitive Behavioral Therapy (MI-CBT) or Treatment as Usual (TAU) with brief education. At 10 weeks, patients initially assigned to TAU switched over to MI-CBT. Compared to patients in the TAU group, patients undergoing MI-CBT were significantly more likely to indicate they were re-initiating DMT (41.7 vs. 14.3%). These significant results were replicated among patients crossing over from TAU to MI-CBT. Treatment satisfaction was high, with 97% of participants reporting that they would recommend MI-CBT to other patients with MS. Results of this pilot study provide initial support for the use of MI-CBT among MS patients who have discontinued treatment against medical advice.Clinicaltrials.gov: NCT01925690.

Entities:  

Keywords:  Adherence; Cognitive behavioral therapy; Disease modifying therapy; Intervention; Motivational interviewing; Multiple sclerosis

Mesh:

Substances:

Year:  2015        PMID: 26563147     DOI: 10.1007/s10865-015-9694-6

Source DB:  PubMed          Journal:  J Behav Med        ISSN: 0160-7715


  26 in total

1.  Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis--results of the βPlus observational cohort study.

Authors:  Carlo Pozzilli; Bernd Schweikert; Ugo Ecari; Wolfgang Oentrich
Journal:  J Neurol Sci       Date:  2011-06-01       Impact factor: 3.181

Review 2.  Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison.

Authors:  Mark S Freedman; Bruce Hughes; Daniel D Mikol; Randy Bennett; Brian Cuffel; Vamil Divan; Nicole LaVallee; Ahmad Al-Sabbagh
Journal:  Eur Neurol       Date:  2008-04-25       Impact factor: 1.710

3.  Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report.

Authors:  Jared M Bruce; Laura M Hancock; Sharon G Lynch
Journal:  Mult Scler       Date:  2009-12-07       Impact factor: 6.312

4.  Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis.

Authors:  D C Mohr; D E Goodkin; W Likosky; N Gatto; K A Baumann; R A Rudick
Journal:  Arch Neurol       Date:  1997-05

5.  Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Authors:  J H Simon; L D Jacobs; M Campion; K Wende; N Simonian; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J J Alam; J S Fischer; D E Goodkin; C V Granger; M Lajaunie; A L Martens-Davidson; M Meyer; J Sheeder; K Choi; A L Scherzinger; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; R H Whitham
Journal:  Ann Neurol       Date:  1998-01       Impact factor: 10.422

6.  Current and emerging therapies in multiple sclerosis: a systematic review.

Authors:  Wanda Castro-Borrero; Donna Graves; Teresa C Frohman; Angela Bates Flores; Paula Hardeman; Diana Logan; Megan Orchard; Benjamin Greenberg; Elliot M Frohman
Journal:  Ther Adv Neurol Disord       Date:  2012-07       Impact factor: 6.570

7.  Motivational interviewing improves weight loss in women with type 2 diabetes.

Authors:  Delia Smith West; Vicki DiLillo; Zoran Bursac; Stacy A Gore; Paul G Greene
Journal:  Diabetes Care       Date:  2007-03-02       Impact factor: 19.112

8.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

Review 9.  Patient autonomy in multiple sclerosis--possible goals and assessment strategies.

Authors:  C Heesen; S Köpke; A Solari; F Geiger; J Kasper
Journal:  J Neurol Sci       Date:  2013-05-25       Impact factor: 3.181

10.  Multiple sclerosis: overview of disease-modifying agents.

Authors:  Alessandro Finkelsztejn
Journal:  Perspect Medicin Chem       Date:  2014-10-05
View more
  5 in total

1.  Baseline predictors of DMT reinitiation among patients with multiple sclerosis following an MI-CBT intervention.

Authors:  Joanie Thelen; Amanda Bruce; Delwyn Catley; Sharon Lynch; Kathy Goggin; Andrea Bradley-Ewing; Morgan Glusman; Abigail Norouzinia; Lauren Strober; Jared Bruce
Journal:  J Behav Med       Date:  2017-11-09

2.  Mediators and moderators of ART adherence effects of supporting treatment adherence readiness through training (START): evidence that START helps vulnerable clients achieve better adherence.

Authors:  Glenn J Wagner; Rachana Seelam; Risa Hoffman; Bonnie Ghosh-Dastidar
Journal:  AIDS Care       Date:  2021-11-21

3.  Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence.

Authors:  Jared M Bruce; Amanda S Bruce; Sharon Lynch; Joanie Thelen; Seung-Lark Lim; Julia Smith; Delwyn Catley; Derek D Reed; David P Jarmolowicz
Journal:  Psychopharmacology (Berl)       Date:  2018-09-22       Impact factor: 4.530

4.  Examining Correlates of Pre-ART and Early ART Adherence to Identify Key Factors Influencing Adherence Readiness.

Authors:  Kyle Gordon; Risa M Hoffman; Gulrez Azhar; Daniel Ramirez; Stefan Schneider; Glenn J Wagner
Journal:  AIDS Behav       Date:  2021-01

5.  Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study.

Authors:  Andrea Zimmer; Michael Coslovsky; Ivo Abraham; Bernhard F Décard
Journal:  Patient Prefer Adherence       Date:  2017-10-20       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.